Breaking News Instant updates and real-time market news.

URGN

UroGen Pharma

$22.95 /

-0.32 (-1.38%)

08:09
11/17/20
11/17
08:09
11/17/20
08:09

UroGen Pharma reports topline results from Optima ll trial for

UroGen Pharma announced final topline results from the single-arm, open-label OPTIMA II Phase 2b trial evaluating the efficacy and safety of investigational UGN-102, mitomycin,for intravesical solution in patients with low-grade intermediate risk non-muscle invasive bladder cancer. As previously reported, 65% (41/63) of patients receiving UGN-102 achieved a complete response (CR) three months after the start of therapy. In this subset of patients, duration of response at nine months was estimated by Kaplan-Meier analysis to be 72.5%. Median duration of response was not reached. The Company expects to initiate a Phase 3 study evaluating UGN-102 versus current standard of care by the end of the year. Treatment with UGN-102 was generally well tolerated and the safety profile was consistent with previously reported results. In the OPTIMA II trial, the majority of the most common adverse events were reported as mild to moderate in severity and include dysuria, urinary frequency, hematuria, urinary urgency, urinary tract infection and fatigue. No treatment related serious adverse events were reported. "The current approach to treating patients diagnosed with low-grade intermediate risk non-muscle invasive bladder cancer is surgery. In most cases, the cancer comes back and repetitive surgical intervention is required. This puts a tremendous burden on patients and their families and can even be life-threatening," said Andrea Maddox-Smith, Chief Executive Officer, Bladder Cancer Advocacy Network. "Being able to provide patients with an alternative, non-surgical treatment option that is effective, well-tolerated and durable, would greatly benefit those in the patient community." Patients with LG IR-NMIBC are chronically relapsing and currently, their only treatment option is repeated transurethral resection of

URGN UroGen Pharma
$22.95 /

-0.32 (-1.38%)

11/10/20 Oppenheimer
UroGen Pharma price target lowered to $40 from $48 at Oppenheimer
09/21/20 JPMorgan
UroGen Pharma price target lowered to $26 from $31 at JPMorgan
04/16/20 H.C. Wainwright
UroGen Pharma price target raised to $57 from $53 at H.C. Wainwright
04/13/20 H.C. Wainwright
UroGen Pharma price target lowered to $53 from $75 at H.C. Wainwright

TODAY'S FREE FLY STORIES

Downgrade
Evotec downgraded to Neutral from Buy at Citi » 05:28
03/05/21
03/05
05:28
03/05/21
05:28
EVTCY

Evotec

$0.00 /

+ (+0.00%)

Citi analyst Nick Nieland…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
EVTCY Evotec
$0.00 /

+ (+0.00%)

EVTCY Evotec
$0.00 /

+ (+0.00%)

01/28/21 RBC Capital
Evotec downgraded to Sector Perform from Outperform at RBC Capital
01/19/21 Deutsche Bank
Evotec downgraded to Hold from Buy at Deutsche Bank
11/20/20 RBC Capital
Evotec price target raised to EUR 32 from EUR 30 at RBC Capital
09/10/20 RBC Capital
Evotec initiated with an Outperform at RBC Capital
Upgrade
J. Front Retailing upgraded to Outperform from Neutral at SMBC Nikko » 05:27
03/05/21
03/05
05:27
03/05/21
05:27
JFROF

J. Front Retailing

$0.00 /

+ (+0.00%)

SMBC Nikko analyst Kuni…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Upgrade
Subsea 7 upgraded to Buy from Hold at Jefferies » 05:26
03/05/21
03/05
05:26
03/05/21
05:26
SUBCY

Subsea 7

$0.00 /

+ (+0.00%)

Jefferies analyst Mark…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SUBCY Subsea 7
$0.00 /

+ (+0.00%)

03/03/21 Berenberg
Subsea 7 price target raised to NOK 105 from NOK 85 at Berenberg
02/26/21 Barclays
Subsea 7 price target raised to NOK 105 from NOK 90 at Barclays
02/26/21 SEB Equities
Subsea 7 downgraded to Hold from Buy at SEB Equities
02/18/21 Jefferies
Subsea 7 downgraded to Hold from Buy at Jefferies
Earnings
Stellus Capital reports Q4 core NII 28c, consensus 27c » 05:26
03/05/21
03/05
05:26
03/05/21
05:26
SCM

Stellus Capital

$11.95 /

-0.1 (-0.83%)

Reports Q4 net asset…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SCM Stellus Capital
$11.95 /

-0.1 (-0.83%)

SCM Stellus Capital
$11.95 /

-0.1 (-0.83%)

05/06/20
Fly Intel: Top five analyst initiations
05/06/20 National Securities
Stellus Capital initiated with a Neutral at National Securities
04/01/20 Janney Montgomery Scott
Janney Montgomery Scott downgrades four BDCs based on COVID-19 recession
04/01/20 Janney Montgomery Scott
Stellus Capital downgraded to Neutral from Buy at Janney Montgomery Scott
SCM Stellus Capital
$11.95 /

-0.1 (-0.83%)

Upgrade
Gol Linhas upgraded to Buy from Hold at Deutsche Bank » 05:23
03/05/21
03/05
05:23
03/05/21
05:23
GOL

Gol Linhas

$6.91 /

-0.405 (-5.54%)

Deutsche Bank analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GOL Gol Linhas
$6.91 /

-0.405 (-5.54%)

GOL Gol Linhas
$6.91 /

-0.405 (-5.54%)

01/28/21 Deutsche Bank
Gol Linhas downgraded to Hold on slowing recovery at Deutsche Bank
01/28/21 Deutsche Bank
Gol Linhas downgraded to Hold from Buy at Deutsche Bank
01/12/21 Deutsche Bank
Gol Linhas price target raised to $15 from $10 at Deutsche Bank
12/21/20 Santander
Gol Linhas downgraded to Hold from Buy at Santander
GOL Gol Linhas
$6.91 /

-0.405 (-5.54%)

GOL Gol Linhas
$6.91 /

-0.405 (-5.54%)

GOL Gol Linhas
$6.91 /

-0.405 (-5.54%)

Upgrade
Latam Airlines upgraded to Hold from Sell at Deutsche Bank » 05:23
03/05/21
03/05
05:23
03/05/21
05:23
LTM

Latam Airlines

$3.18 /

+ (+0.00%)

Deutsche Bank analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LTM Latam Airlines
$3.18 /

+ (+0.00%)

11/09/20 Seaport Global
Azul upgraded to Buy from Neutral at Seaport Global
05/28/20 BofA
Latam Airlines reinstated with an Underperform at BofA
05/27/20 Deutsche Bank
Latam Airlines downgraded to Sell from Hold at Deutsche Bank
05/26/20 Raymond James
Latam Airlines downgraded to Underperform from Outperform at Raymond James
Upgrade
Exxon Mobil upgraded to Hold from Sell at DZ Bank » 05:22
03/05/21
03/05
05:22
03/05/21
05:22
XOM

Exxon Mobil

$58.74 /

+2.22 (+3.93%)

DZ Bank analyst Werner…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
XOM Exxon Mobil
$58.74 /

+2.22 (+3.93%)

XOM Exxon Mobil
$58.74 /

+2.22 (+3.93%)

03/04/21 MKM Partners
Exxon Mobil price target raised to $60 from $56 at MKM Partners
03/04/21 Morgan Stanley
Exxon Mobil price target raised to $60 from $57 at Morgan Stanley
03/04/21 Truist
Exxon Mobil price target raised to $60 from $50 at Truist
03/04/21 Citi
Exxon Mobil price target raised to $53 from $44 at Citi
XOM Exxon Mobil
$58.74 /

+2.22 (+3.93%)

XOM Exxon Mobil
$58.74 /

+2.22 (+3.93%)

XOM Exxon Mobil
$58.74 /

+2.22 (+3.93%)

XOM Exxon Mobil
$58.74 /

+2.22 (+3.93%)

Hot Stocks
Dada Nexus, Unilever announce livestreaming e-commerce event partnership » 05:22
03/05/21
03/05
05:22
03/05/21
05:22
DADA

Dada Nexus

$32.13 /

-2.77 (-7.94%)

, UL

Unilever

$53.52 /

+0.11 (+0.21%)

Dada Group (DADA) and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DADA Dada Nexus
$32.13 /

-2.77 (-7.94%)

UL Unilever
$53.52 /

+0.11 (+0.21%)

DADA Dada Nexus
$32.13 /

-2.77 (-7.94%)

01/18/21 CICC
Dada Nexus initiated with an Outperform at CICC
01/07/21 KeyBanc
Dada Nexus initiated with an Overweight at KeyBanc
12/08/20
Fly Intel: Top five analyst downgrades
12/08/20 Morgan Stanley
Dada Nexus downgraded to Equal Weight on competition risk at Morgan Stanley
UL Unilever
$53.52 /

+0.11 (+0.21%)

02/08/21 Barclays
Unilever price target lowered to EUR 48 from EUR 55 at Barclays
12/08/20 Investec
Unilever upgraded to Buy from Hold at Investec
12/03/20 Societe Generale
Unilever initiated with a Buy at Societe Generale
11/25/20 Jefferies
Jefferies sees 'strong buying opportunity' upcoming after Unilever unification
DADA Dada Nexus
$32.13 /

-2.77 (-7.94%)

  • 03
    Dec
  • 05
    Jun
UL Unilever
$53.52 /

+0.11 (+0.21%)

DADA Dada Nexus
$32.13 /

-2.77 (-7.94%)

DADA Dada Nexus
$32.13 /

-2.77 (-7.94%)

Downgrade
Wipro downgraded to Sell from Reduce at ICICI Securities » 05:22
03/05/21
03/05
05:22
03/05/21
05:22
WIT

Wipro

$6.44 /

-0.02 (-0.31%)

ICICI Securities analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
WIT Wipro
$6.44 /

-0.02 (-0.31%)

WIT Wipro
$6.44 /

-0.02 (-0.31%)

12/21/20 Goldman Sachs
Wipro resumed with a Sell at Goldman Sachs
10/14/20 Investec
Wipro downgraded to Hold from Buy at Investec
10/06/20 ICICI Securities
Wipro downgraded to Hold from Buy at ICICI Securities
07/16/20 Wedbush
Infosys upgraded to Outperform on improving visibility at Wedbush
WIT Wipro
$6.44 /

-0.02 (-0.31%)

Upgrade
Energias de Portugal upgraded to Buy from Hold at Societe Generale » 05:21
03/05/21
03/05
05:21
03/05/21
05:21
EDPFY

Energias de Portugal

$0.00 /

+ (+0.00%)

Societe Generale analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EDPFY Energias de Portugal
$0.00 /

+ (+0.00%)

01/20/21 Morgan Stanley
Energias de Portugal resumed with an Overweight at Morgan Stanley
09/21/20 RBC Capital
Energias de Portugal upgraded to Sector Perform at RBC Capital
09/16/20 Credit Suisse
Energias de Portugal price target raised to EUR 5 at Credit Suisse
08/28/20 JPMorgan
Energias de Portugal price target raised to EUR 4.65 from EUR 4.50 at JPMorgan
Downgrade
Roche downgraded to Hold from Buy at Erste Group » 05:20
03/05/21
03/05
05:20
03/05/21
05:20
RHHBY

Roche

$0.00 /

+ (+0.00%)

Erste Group analyst Hans…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

03/03/21 Goldman Sachs
Adaptive Biotechnologies downgraded to Neutral from Buy at Goldman Sachs
02/25/21 Berenberg
Roche price target lowered to CHF 320 from CHF 325 at Berenberg
02/24/21 Morgan Stanley
Roche price target lowered to CHF 345 from CHF 365 at Morgan Stanley
02/23/21 BofA
BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Upgrade
Amadeus IT Group upgraded to Buy from Hold at Erste Group » 05:20
03/05/21
03/05
05:20
03/05/21
05:20
AMADY

Amadeus IT Group

$0.00 /

+ (+0.00%)

Erste Group analyst Hans…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AMADY Amadeus IT Group
$0.00 /

+ (+0.00%)

AMADY Amadeus IT Group
$0.00 /

+ (+0.00%)

03/02/21 UBS
Amadeus IT Group price target lowered to EUR 61 from EUR 65 at UBS
03/01/21 JPMorgan
Amadeus IT Group price target raised to EUR 58 from EUR 50 at JPMorgan
03/01/21 Oddo BHF
Amadeus IT Group upgraded to Neutral from Reduce at Oddo BHF
03/01/21 Oddo BHF
Amadeus IT Group upgraded to Neutral from Reduce at Oddo BHF
Initiation
Cadeler initiated with a Buy at Kepler Cheuvreux » 05:19
03/05/21
03/05
05:19
03/05/21
05:19
CADLF

Cadeler

$0.00 /

+ (+0.00%)

Kepler Cheuvreux…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CADLF Cadeler
$0.00 /

+ (+0.00%)

01/06/21 DNB Markets
Cadeler initiated with a Buy at DNB Markets
Earnings
GSX Techedu reports Q4 EPS (39c), consensus (38c) » 05:19
03/05/21
03/05
05:19
03/05/21
05:19
GSX

GSX Techedu

$84.11 /

-2.9 (-3.33%)

Reports Q4 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GSX GSX Techedu
$84.11 /

-2.9 (-3.33%)

GSX GSX Techedu
$84.11 /

-2.9 (-3.33%)

02/01/21 JPMorgan
GSX Techedu downgraded to Underweight from Neutral at JPMorgan
01/29/21
GSX Techedu downgraded to Sell from Neutral at China Merchants
01/28/21 Goldman Sachs
GSX Techedu downgraded to Sell from Neutral at Goldman Sachs
12/17/20
Fly Intel: Top five analyst downgrades
GSX GSX Techedu
$84.11 /

-2.9 (-3.33%)

GSX GSX Techedu
$84.11 /

-2.9 (-3.33%)

GSX GSX Techedu
$84.11 /

-2.9 (-3.33%)

GSX GSX Techedu
$84.11 /

-2.9 (-3.33%)

Upgrade
AXA upgraded to Conviction Buy from Buy at Bryan Garnier » 05:19
03/05/21
03/05
05:19
03/05/21
05:19
AXAHY

AXA

$0.00 /

+ (+0.00%)

Bryan Garnier analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AXAHY AXA
$0.00 /

+ (+0.00%)

03/03/21 Deutsche Bank
AXA price target raised to EUR 25 from EUR 24.50 at Deutsche Bank
03/02/21 Morgan Stanley
AXA price target lowered to EUR 24 from EUR 24.20 at Morgan Stanley
03/01/21 Berenberg
AXA price target raised to EUR 23.30 from EUR 21.50 at Berenberg
02/26/21 RBC Capital
AXA price target raised to EUR 24 from EUR 23 at RBC Capital
AXAHY AXA
$0.00 /

+ (+0.00%)

Upgrade
Meggitt upgraded to Outperform from Neutral at Exane BNP Paribas » 05:18
03/05/21
03/05
05:18
03/05/21
05:18
MEGGF

Meggitt

$0.00 /

+ (+0.00%)

Exane BNP Paribas analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MEGGF Meggitt
$0.00 /

+ (+0.00%)

02/11/21 Morgan Stanley
Meggitt price target lowered to 455 GBp from 465 GBp at Morgan Stanley
02/04/21 Jefferies
Meggitt price target raised to 500 GBp from 375 GBp at Jefferies
01/08/21 JPMorgan
Meggitt price target lowered to 390 GBp from 395 GBp at JPMorgan
12/15/20 Panmure Gordon
Meggitt downgraded to Sell from Hold at Panmure Gordon
Upgrade
Woodside Petroleum upgraded to Overweight from Neutral at JPMorgan » 05:17
03/05/21
03/05
05:17
03/05/21
05:17
WOPEY

Woodside Petroleum

$0.00 /

+ (+0.00%)

JPMorgan analyst Mark…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
WOPEY Woodside Petroleum
$0.00 /

+ (+0.00%)

12/09/20 JPMorgan
Woodside Petroleum downgraded to Neutral from Overweight at JPMorgan
07/17/20 Citi
Woodside Petroleum downgraded to Neutral from Buy at Citi
06/25/20 JPMorgan
Woodside Petroleum upgraded to Overweight from Neutral at JPMorgan
05/05/20 Bernstein
Woodside Petroleum upgraded to Outperform from Market Perform at Bernstein
Downgrade
Brembo downgraded to Reduce from Hold at Kepler Cheuvreux » 05:16
03/05/21
03/05
05:16
03/05/21
05:16
BRBOF

Brembo

$0.00 /

+ (+0.00%)

Kepler Cheuvreux analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BRBOF Brembo
$0.00 /

+ (+0.00%)

02/01/21 Exane BNP Paribas
Brembo downgraded to Underperform from Neutral at Exane BNP Paribas
Upgrade
Belimo Holding upgraded to Hold from Reduce at Kepler Cheuvreux » 05:15
03/05/21
03/05
05:15
03/05/21
05:15
BLHWF

Belimo Holding

$0.00 /

+ (+0.00%)

Kepler Cheuvreux analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BLHWF Belimo Holding
$0.00 /

+ (+0.00%)

12/11/20 Berenberg
Belimo Holding price target raised to CHF 8,250 from CHF 8,000 at Berenberg
05/26/20 UBS
Belimo Holding price target lowered to CHF 5,150 from CHF 5,200 at UBS
03/18/20 Berenberg
Belimo Holding upgraded to Buy from Hold at Berenberg
Earnings
ObsEva reports Q4 EPS (32c), consensus (42c) » 05:15
03/05/21
03/05
05:15
03/05/21
05:15
OBSV

ObsEva

$3.37 /

-0.32 (-8.67%)

As of December 31, 2020,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
OBSV ObsEva
$3.37 /

-0.32 (-8.67%)

OBSV ObsEva
$3.37 /

-0.32 (-8.67%)

01/04/21 H.C. Wainwright
ObsEva price target lowered to $17 from $23 at H.C. Wainwright
11/09/20 JPMorgan
ObsEva downgraded to Underweight from Neutral at JPMorgan
10/05/20 H.C. Wainwright
ObsEva price target lowered to $23 from $36 at H.C. Wainwright
07/07/20 Wedbush
Selloff in ObsEva shares 'overdone,' says Wedbush
OBSV ObsEva
$3.37 /

-0.32 (-8.67%)

  • 30
    Oct
OBSV ObsEva
$3.37 /

-0.32 (-8.67%)

OBSV ObsEva
$3.37 /

-0.32 (-8.67%)

Initiation
Technip Energies initiated with a Buy at Kepler Cheuvreux » 05:15
03/05/21
03/05
05:15
03/05/21
05:15
THNPF

Technip Energies

$0.00 /

+ (+0.00%)

Kepler Cheuvreux…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
THNPF Technip Energies
$0.00 /

+ (+0.00%)

03/01/21 Exane BNP Paribas
Technip Energies initiated with a Neutral at Exane BNP Paribas
03/01/21 Morgan Stanley
Technip Energies initiated with an Overweight at Morgan Stanley
02/22/21 Barclays
Technip Energies initiated with an Equal Weight at Barclays
Upgrade
Barclays upgraded to Add from Sell at AlphaValue » 05:14
03/05/21
03/05
05:14
03/05/21
05:14
BCS

Barclays

$9.21 /

-0.235 (-2.49%)

AlphaValue upgraded…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BCS Barclays
$9.21 /

-0.235 (-2.49%)

BCS Barclays
$9.21 /

-0.235 (-2.49%)

02/23/21 JPMorgan
Barclays price target raised to 190 GBp from 180 GBp at JPMorgan
02/22/21 RBC Capital
Barclays price target raised to 150 GBp from 140 GBp at RBC Capital
02/19/21 Deutsche Bank
Barclays price target raised to 200 GBp from 180 GBp at Deutsche Bank
01/28/21 Berenberg
Barclays price target raised to 180 GBp from 160 GBp at Berenberg
BCS Barclays
$9.21 /

-0.235 (-2.49%)

BCS Barclays
$9.21 /

-0.235 (-2.49%)

BCS Barclays
$9.21 /

-0.235 (-2.49%)

BCS Barclays
$9.21 /

-0.235 (-2.49%)

Upgrade
Henkel upgraded to Hold from Sell at Nord/LB » 05:13
03/05/21
03/05
05:13
03/05/21
05:13
HENKY

Henkel

$0.00 /

+ (+0.00%)

Nord/LB analyst Thorsten…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
HENKY Henkel
$0.00 /

+ (+0.00%)

01/12/21 UBS
Henkel price target raised to EUR 81 from EUR 80 at UBS
01/05/21 Barclays
Barclays trims Henkel Adhesive estimates on slower recovery expectations
12/03/20 JPMorgan
Henkel upgraded to Overweight from Neutral at JPMorgan
11/30/20 Commerzbank
Henkel upgraded to Buy from Hold at Commerzbank
Hot Stocks
Moderna announces Takeda NDA submission to distribute COVID-19 vaccine in Japan » 05:12
03/05/21
03/05
05:12
03/05/21
05:12
MRNA

Moderna

$132.21 /

+1.01 (+0.77%)

, TAK

Takeda Pharmaceutical

$17.45 /

-0.25 (-1.41%)

Moderna (MRNA) announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRNA Moderna
$132.21 /

+1.01 (+0.77%)

TAK Takeda Pharmaceutical
$17.45 /

-0.25 (-1.41%)

MRNA Moderna
$132.21 /

+1.01 (+0.77%)

03/01/21 Chardan
Moderna price target raised to $182 from $107 at Chardan
02/26/21 Barclays
Moderna price target raised to $178 from $169 at Barclays
02/26/21 Brookline
Moderna price target raised to $205 from $180 at Brookline
02/25/21 Piper Sandler
Moderna transitioning into profitable company, says Piper Sandler
TAK Takeda Pharmaceutical
$17.45 /

-0.25 (-1.41%)

03/03/21 RBC Capital
Ovid downgraded to Sector Perform at RBC Capital after rally on Takeda deal
01/29/21 Morgan Stanley
Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout
12/29/20 Needham
Needham names Phathom Pharmaceuticals Top Pick for 2021
12/15/20 Needham
Phathom Pharmaceuticals price target raised to $55 from $45 at Needham
MRNA Moderna
$132.21 /

+1.01 (+0.77%)

  • 19
    May
MRNA Moderna
$132.21 /

+1.01 (+0.77%)

TAK Takeda Pharmaceutical
$17.45 /

-0.25 (-1.41%)

MRNA Moderna
$132.21 /

+1.01 (+0.77%)

TAK Takeda Pharmaceutical
$17.45 /

-0.25 (-1.41%)

MRNA Moderna
$132.21 /

+1.01 (+0.77%)

TAK Takeda Pharmaceutical
$17.45 /

-0.25 (-1.41%)

Recommendations
Costco price target lowered to $395 from $410 at Baird » 05:07
03/05/21
03/05
05:07
03/05/21
05:07
COST

Costco

$319.35 /

-4.53 (-1.40%)

Baird analyst Peter…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
COST Costco
$319.35 /

-4.53 (-1.40%)

COST Costco
$319.35 /

-4.53 (-1.40%)

02/03/21 Baird
Costco January core comps re-accelerated, says Baird
02/02/21 Cleveland Research
Costco U.S. sales slightly improved in January, says Cleveland Research
01/07/21 Deutsche Bank
Costco price target raised to $347 from $344 at Deutsche Bank
01/06/21 Baird
Costco saw some deceleration in December core comp sales, says Baird
COST Costco
$319.35 /

-4.53 (-1.40%)

COST Costco
$319.35 /

-4.53 (-1.40%)

COST Costco
$319.35 /

-4.53 (-1.40%)

COST Costco
$319.35 /

-4.53 (-1.40%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.